Tuesday, May 25, 2021 8:25:12 PM
In CD12 everything was not proper , somehow..
Yeah, "somehow"....cough cough....wonder how that might have happened. Probably zero chance the deck was stacked against us, right? (mad emoji here)
Also, I previously brought up the issue with Blood type A vs Blood type O. Type A being found to have higher rate of mortality than type O. It would be nice if this was also factored into the patient distribution but in doing so it could potentially cause serious delays in finding qualified participants in a timely manner. Dr Kelly responded as follows:
xxxxxxx,
Thank you for reaching out to us.
As you know, CytoDyn welcomes dialogue with shareholders, and we pride ourselves on the transparency we provide to investors and the market.
However, as a public company, CytoDyn has “fair disclosure” obligations under Regulation FD, 17 CFR Part 243. The company is prohibited by federal law from disclosing material non-public information except in a public disclosure or under specifically enumerated conditions. Selective disclosure of material non-public information would violate our Regulation FD obligations and expose CytoDyn to potential litigation and regulatory actions.
We take seriously our obligation to protect material non-public information. Therefore we provide investors information in various public forums, including securities filings, press releases, and investor calls. We try to answer all questions on the investor’s conference call, but we can’t always promise every question will be answered despite our best intentions.
We invite you to submit additional questions in a publicly available forum, such as an investors call.
Best,
Scott
Scott A. Kelly, MD
Chief Medical Officer, Chairman of the Board, Head of Business Development
CytoDyn Inc. (www.cytodyn.com)
1111 Main Street, Suite 660
Vancouver, Washington 98660
E-mail: skelly@cytodyn.com
Office: (360) 980-8524
Facsimile: (360) 799-5954
Mobile: (404) 229-6606
All IMHO
"Falsus in unum, falsus in omnibus" / “Lie about one thing, lie about it all”
"The greatest obstacle to discovering the shape of the earth, the continents, and the oceans was not ignorance, but the illusion of knowledge" -Daniel J. Boorstin
Recent CYDY News
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
